

December 12, 2010

HSS – America’s Number One Orthopedic Center Selects Medical Compression Systems (MCS).

**Over 5,000 procedures relevant to MCS are performed annually at this New
York medical center.**

According to Adi Dagan, MCS’s CEO: “The use of the company’s device by America’s number one orthopedic hospital, HSS, is the jewel in the crown that has been added to the leading medical centers already using ActiveCare+S.F.T®.” Medical Compression Systems (MCS), which is active in the non-invasive medical device field and traded on the TASE, announced today (December 12, 2010) that the Hospital for Special Surgery (HSS), which was recently voted the number one orthopedic hospital in the USA by U.S. News&World Report, has begun using ActiveCare+S.F.T for venous thrombosis prevention. Over 5,000 procedures relevant to the company are performed at this hospital annually.

According to Dr. Douglas Padgett, head of the Adult Hip Rehabilitation and Surgery Unit at HSS: “This device is as effective as blood thinners in reducing blood clots following hip replacement surgery and is safer to use. The device has the potential to change the paradigm with respect to preventing the formation of blood clots after hip replacement surgery and later on also in knee replacement surgery until it becomes possible to eliminate the need for blood thinners.

-contd-

Adi Dagan, CEO of MCS added: “Starting to work with HSS comprises the closing of an amazing year during which MCS has completed the market entry phase. The company has an extensive user base of opinion-leading centers among them 3 of the top 10 centers and other hospitals as well. The choice of ActiveCare+S.F.T® by these centers also constitutes clinical and economic approval for other USA hospitals to decide to change over to using the company’s device instead of anticoagulant drugs.” He adds, “Without a doubt, HSS is the crown jewel for us. We are pleased that it has joined the other hospitals already using the device.”

About MCS:

MCS is engaged in the field of non-invasive medical device for the improvement of peripheral blood circulation and has developed a device to prevent deep vein thrombosis (DVT) resulting from trauma or surgical intervention. The company has FDA approval to market and sell its products in the USA and CE approval to market and sell them in Europe.

Forward-looking information

The company’s estimates included in this publication, including with respect to the anticipated volume of its activities, is forward-looking information, as defined in the Securities Law, 5728-1968, and it is uncertain that this information will be realized. The company’s estimates are based on business assumptions, past experience, and professional knowledge. These evaluations may not materialize, in whole or in part, or may materialize in a substantially different manner from what the company expects, for various reasons, including changes in the market trends, competition, global or local economic situation, and regulatory changes.

Media Contact:

Vered Rahat

Email: vered.rahata@gmail.com

Tel: +972-52-800-0380

###